

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1102CON3SERIAL NO.:  
10/694,559

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Robert F. KAIKO et al.FILING DATE:  
October 27, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S.T	AA	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65	
	AB	3	1	3	3	1	3	2	05/12/64	Loeb, et al.	264	49	
	AC	3	1	7	3	8	7	6	03/16/65	Zobrist	252	137	
	AD	3	2	7	6	5	8	6	10/04/66	Rosaen	210	90	
	AE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285	
	AF	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260	
	AG	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260	
	AH	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260	
S.T	AI	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S.T	AJ	8	3	0	3	1	9	7	9/83	WO	A61K	9/22		
	AK	9	0	0	4	9	6	5	05/17/1990	WO	A61K	31/485		
	AL	9	4	0	6	4	2	6	3/94	WO	A61K	31/46		
	AM	9	5	0	3	8	0	4	2/95	WO	A61K	31/485		
S.T	AN	9	6	0	2	2	5	1	2/96	WO	A61K	31/485		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

S.T	AO	Foss, J.F., et al. Abstract, "Prevention of Apomorphine- or Cisplatin- Induced emesis in the dog by combination of Methylnaltrexone and Morphine", Cancer Chemother Pharmacol (1998); 42(4):287-91.
	AP	Yuan et al., "Efficacy of Orally Administered Methylnaltrexone in Decreasing Subjective Effects After Intravenous Morphine", Drug and Alcohol Dependence (1998); 52:161-165.
	AQ	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.
	AR	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.
	AS	Yuan et al., "The Safety and Efficacy of Oral Methylnaltrexone in Preventing Morphine-Induced Delay in Oral-Cecal Transit Time", Clinical Trials and Therapeutics (1997), 61:467-475.
	AT	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.
S.T	AU	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).

EXAMINER

S.T

DATE CONSIDERED

7/19/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	BA	3 9 1 6 8 8 9	11/04/1975	Russell	128	145.8	
	BB	3 9 6 5 2 5 6	06/22/1976	Leslie	424	22	
	BC	3 9 6 6 9 4 0	6/76	Pachler et al.	424	260	
	BD	4 1 7 6 1 8 6	11/79	Goldberg	424	260	
S.T.	BE	4 2 3 7 1 4 0	12/02/1980	Dudzinski	424	260	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
S.T.	BF	9 7 3 3 5 6 6	9/97	WO	A61K	9/20	
	BG	9 8 3 5 6 7 9	8/98	WO	A61K	31/485	
	BH	9 9 3 2 1 2 0	7/99	WO	A61K	31/485	
	BI	0 0 0 1 3 7 7	01/13/2000	WO	A61K	31/00	
S.T.	BJ	8 7 0 1 2 8 2	03/12/1987	WO	A61K	31/485	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
S.T.	BK	Chih-Cheng Chien, et al., "Sigma Antagonists Potentiate Opioid Analgesia in Rats", Neuroscience Letters 190 (1995), 137-139.					
	BL	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995) 92:10540-10544.					
	BN	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.					
	BO	Talwin NX, Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ 2120-2121.					
	BP	Foss et al., "Dose related Antagonism of the Emetic Effect of Morphine by Methylnaltrexone in Dogs", J. Clin Pharmacol (1993), 33:747-751					
	BQ	Holmes et al., "Inhibiting Spinal Dynorphin A Component Enhances Intrathecal Morphine Antinociception in Mice", Anesth. Analg. (1993), 77:1166-73.					
S.T.	BR	Miakowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 30:263-274.					
EXAMINER  S.T.				DATE CONSIDERED  2/19/04			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL	CA	CB	CC	CD	CE	CF	CG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.								4 2 8 5 9 8 7	08/25/1981	Ayer, et al.	427	3		
								4 3 6 6 3 1 0	12/28/1982	Leslie	536	56		
								4 4 0 1 6 7 2	8/83	Portoghese et al.	424	260		
								4 4 4 3 4 2 8	04/17/1984	Oshlack et al.	424	22		
								4 4 5 1 4 7 0	5/84	Ganti	424	260		
								4 4 5 7 9 3 3	7/84	Gordon et al.	424	260		
S.T.								4 4 6 4 3 7 8	8/84	Hussain et al.	424	260		
								<b>FOREIGN PATENT DOCUMENTS</b>						
								DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S.T.								0 1 3 2 1 8 0	05/10/2001	WO (A2)	A61K	31/485		
								0 1 6 8 0 8 0	09/20/2001	WO (A2)	A61K	31/00		
								0 1 3 7 7 8 5	05/31/2001	WO (A2)	A61K			
								0 1 5 2 8 5 1	07/26/2001	WO (A1)	A61K	31/485		
S.T.								0 1 8 5 2 5 7	11/15/2001	WO (A2)	A61P			
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S.T.	CM	Weinhold et al., "Buprenorphine Alone and in Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.												
	CN	Cappel et al., "Enhancement of Naloxone Induced Analgesia by Pretreatment with Morphine" Pharma. Bioch. & Behav. (1989), 34:425-427.												
	CO	Vaccaro et al., "Analgesia Produced by Normal Doses of Opioid Antagonists Alone and in Combination with Morphine", Pain (1989), 36:103-109.												
	CP	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.												
	CQ	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.												
	CR	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. Clin. Pharmacol (1981), 21:162-168.												
S.T.	CS	Translation of German patent application DE 43 25 465												
EXAMINER S.T.										DATE CONSIDERED 7/19/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	DA	4 5 7 3 9 9 5	3/86	Chen et al.	604	896	
	DB	4 5 8 2 8 3 5	4/86	Lewis et al.	514	282	
	DC	4 6 0 8 3 7 6	8/86	Pasternak	514	282	
	DD	4 6 6 1 4 9 2	4/87	Lewis et al.	514	282	
	DE	4 7 1 9 2 1 5	1/88	Goldberg	514	282	
	DF	4 7 3 0 0 4 8	3/88	Portoghese et al.	546	45	
S.T.	DG	4 7 6 0 0 6 9	7/88	Rzeszolarski et al.	514	282	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
S.T.	DH	0 1 9 3 8 5 2	12/31/2001	WO (A2)	A61K	31/00	
	DI	0 9 1 3 1 5 2	6/99	EP	A61K	31/485	
	DJ	0 6 4 7 4 4 8	4/95	EP	A61K	31/485	
	DK	0 3 5 2 3 6 1	1/90	EP	A61K	31/485	
S.T.	DL	0 2 0 5 2 8 2	12/86	EP	A61K	9/22	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
S.T.	DM	Alvarez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Ora Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.					
	DN	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52:659-663.					
	DO	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone Research Monograph 28 (1980) p. 3-9.					
	DP	Baum et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 p. 426-429.					
	DQ	Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 55-83.					
S.T.	DR	Bloom et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol 2, p. 1342-1349.					
EXAMINER  S.T.			DATE CONSIDERED  7/19/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	EA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S T	EA	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282		
	EB	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
	EC	4	8	0	3	2	0	8	2/89	Pasternak	514	282		
	ED	4	8	0	6	3	4	1	2/89	Chien et al.	424	448		
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464		
	EF	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381		
S T	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S T	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
	EI	0	3	1	9	2	4	3	06/07/1989	EP (A1)	A61K	31/485		
	EJ	0	3	1	9	2	4	3	11/07/1990	EP (B1)	A61K	31/485		
	EK	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		
S T	EL	29	7	1	9	7	0	4	2/97	DE	A61K	31/485		
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S T	EM	Briscoe et al., "Methoclocinnamox: Time Course of Changes in Alfentanil-Reinforced Rhesus Monkeys"; Psychopharmacology (2000) 148:393-399.												
	EN	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) p. 545-551.												
	EO	Bullingham et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm (1983) 8: 332-343.												
	EP	Calimlim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and There (1974) Vol. 15; No. 6 pp.556-564.												
	EQ	Caruso et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pp.1336-1341F. 1997												
S T	ER	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May;51 (5) pp. 713-737.												
	ES	Chiang, et al. "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pp.1-8.												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	FA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	FA	4	8	3	4	9	6	5	05/30/1989	Martani et al.	424	488		
	FB	4	8	3	4	9	8	4	05/30/1989	Goldie et al.	424	488		
	FC	4	8	3	4	9	8	5	05/30/1989	Elger et al.	424	488		
	FD	4	8	4	4	9	0	7	07/04/1989	Elger et al.	424	465		
	FE	4	8	4	4	9	0	9	07/04/1989	Goldie et al.	424	480		
	FF	4	8	4	4	9	1	0	07/04/1989	Leslie et al.	424	494		
S.T.	FG	4	8	6	1	5	9	8	8/89	Oshlak et al.	424	468		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S.T.	FH	4	3	2	5	4	6	5	2/95	DE	A61K	31/485		x
	FI	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
	FJ	9	8	2	5	6	1	3	06/18/98	WO	A61K	31/485	abstract	
S.T.	FK	0	0	3	8	6	4	9	07/06/00	WO	A61K	9/00	abstract	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S.T.	FL	Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin Pharmacol Thera (1984) Vol 36 No. 5, pp.704-708.												
	FM	Comer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects Of Heroin un Humans"; Psychopharmacology (2002) 159, pp.351-360.												
	FN	Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist"; Clinical Pharmacy, Vol. 3 (1984) pp.273-280.												
	FO	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999)pp.1-11.												
	FP	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp.121-131.												
	FQ	Fink et al., "naloxone in Heroin Dependence"; Clin Pharm and Thera. Vol 9, No. 5;pp.568-577. 1999												
S.T.	FR	Fishman et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic Dependent Men"; J. Pharm. And Exper. Thera (1973)Vol 10 No. 2;pp.575-580.												
EXAMINER  S.T.										DATE CONSIDERED  7/19/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	GA	4 8 6 1 7 8 1	8/89	Goldberg	514	282	
	GB	4 8 6 7 9 8 5	09/19/1989	Heafield et al.	424	461	
	GC	4 8 7 3 0 7 6	10/89	Fishman et al.	412	10	
	GD	4 8 8 2 3 3 5	11/89	Sindair	514	282	
	GE	4 8 8 9 8 6 0	12/89	Rzeszotarski et al.	514	282	
	GF	4 9 3 5 4 2 8	6/90	Lewis	514	282	
S.T.	GG	4 9 4 0 5 8 7	07/10/1990	Jenkins et al.	424	480	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
S.T.	GH	00 1 5 8 4 7 7	8/16/01	WO	A61P	abstract	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
S.T.	GI	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I (1990) Vol 10, No. 2; pp.375-386.					
S.T.	GJ	Freye et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary light Reflex"; Arzneimittel-Forsch/Drug Res. 50(1)(2000)pp. 24-30.					
	GK	Fudala, et al., "Effects of Buprenorphine asnd Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8.					
	GL	Fudala et al., "Human Pharmacology and Abuse Potential Of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pp. 300-306.					
	GM	Gal et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 537-542.					
S.T.	GN	Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pp. 35-41.					
	GO	Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113.					
EXAMINER <div style="text-align: center;">S.T.</div>				DATE CONSIDERED <div style="text-align: center;">7/19/04</div>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	HA	4	2	0	0	0	9	8	04/29/1980	Ayer, et al.	128	260		
	HB	4	9	7	0	0	7	5	11/13/1990	Oshlak	424	451		
	HC	4	9	8	7	1	3	6	01/22/1991	Kreek et al.	514	282		
	HD	4	9	9	0	3	4	1	02/05/1991	Goldie et al.	424	484		
	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497		
	HF	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282		
S.T.	HG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S.T.	HH	00	1	8	5	1	5	0	11/15/01	WO	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
S.T.	HI	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol.17, No.3, pp. 193-197												
	HJ	Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, pp. 1639-1647.												
	HK	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting $\mu$ Opioids in Drug Abusers"; J. Pharm and Exper Thera (1996) Vol 277, No 3, pp. 1228-1236.												
	HL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol 29, pp. 33-39.												
	HM	Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arznieim-Forsch/Drug Res. 35 (No II)(1985)pp. 1742-1744.												
	HN	Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pp. 173-176.												
S.T.	HO	Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) Vol 307, pp. 251-257.												
EXAMINER  S.T.										DATE CONSIDERED  2/19/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	ID	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S.T.	IA	5 0 9 1 1 8 9	02/25/1992	Heafield et al.	424	457	
	IB	5 0 9 6 7 1 5	3/92	Sinclair	424	449	
	IC	5 1 0 2 8 8 7	4/92	Goldberg	514	282	
	ID	4 1 6 0 0 2 0	07/03/1979	Ayer, et al.	424	15	
	IE	5 1 4 9 5 3 8	9/92	Granger et al.	424	449	
	IF	5 2 1 5 7 5 8	06/01/1993	Krishnamurthy	424	488	
S.T.	IG	5 2 2 5 4 4 0	7/93	London et al.	514	535	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
S.T.	IH	00 0 6 7 7 3 9	11/16/00	WO	A61K	31/00	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
S.T.	IJ	Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846.					
	IK	Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174.					
	IL	Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211.					
	IM	Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458.					
	IN	Stine et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209.					
	IO	Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242.					
	IP	Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993.					
	IQ	Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383.					
	IR	Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634.					
S.T.	IS	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages					
EXAMINER <div style="text-align: center; font-size: 1.5em;">S.T.</div>				DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">2/19/04</div>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	ID	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ST	JA	5 2 2 6 3 3 1	07/13/1993	Thompson et al.	73	865.9	
	JB	5 2 3 6 7 1 4	8/93	Lec et al.	424	449	
	JC	5 2 5 6 6 6 9	10/93	Askanazi et al.	514	282	
	JD	5 2 6 6 3 3 1	11/30/1993	Oshlak et al.	424	468	
	JE	5 2 7 3 7 6 0	12/93	Oshlak et al.	424	486	
	JF	5 2 8 6 4 9 3	02/15/1994	Oshlak et al.	424	468	
ST	JG	5 3 1 6 7 5 9	12/93	Rose et al.	424	10	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
ST	JH	00 0 5 1 5 9 2	9/05/00	WO	A61K	31/14	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
ST	JJ	Umbrecht et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56 pp. 181-190					
ST	JK	Vaccarino et al., "Enogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034.					
ST	JL	Wang et al., "Inverse Agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) Vol 77, pp. 1590-1600.					
	JM	<del>Way et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261.</del>					
ST	JN	Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) Vol 44, No 3, pp. 335-342.					
	JO	Wells, et al., "In vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid $\mu$ -Agonist/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper Thera (2001) Vol 297, No 2, pp. 597-605					
	JP	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pp. 4-6.					
	JQ	Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pp. 139-148.					
ST	JR	Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pp. 325-336.					
EXAMINER ST				DATE CONSIDERED 7/19/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Robert F. KAIKO et al.									
						FILING DATE: October 27, 2003		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>															
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	KA	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282			
	KB	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25			
	KC	5	3	2	4	3	5	1	06/28/1994	Oshlak et al.	106	153			
	KD	5	3	3	6	6	9	1	08/09/1994	Raffa et al.	514	629			
	KE	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279			
	KF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289			
S.T.	KG	5	3	5	6	4	6	7	10/18/1994	Oshlak et al.	106	153			
<b>FOREIGN PATENT DOCUMENTS</b>															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
S.T.	KH	0	1	5	8	4	5	1	08/19/2001	WO (A1)	A61K	31/485			
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
S.T.	KI	Han et al., "Mucocoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) Vol 177, pp. 201-209.													
	KJ	Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pp. 438-445.													
	KK	Harris et al., "Buprenorphine and Naloxone co-administration in opiate dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pp. 85-94.													
	KL	Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pp. 625-630.													
	KM	Högger et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) Vol 37, No 8, pp. 377-385													
S.T.	KN	Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011.													
	KO	<del>Crain et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence"</del>													
S.T.	KP	Howes et al., "The Pharmacology of TR5109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105.													
S.T.	KQ	Leeling et al., "Disposition and metabolism of codorphone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp 649-653.													
EXAMINER <div style="text-align: center;">S.T.</div>										DATE CONSIDERED <div style="text-align: center;">9/19/04</div>					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559						
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)						APPLICANT(S): Robert F. KAIKO et al.								
						FILING DATE: October 27, 2003		GROUP: 1615						
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T	LA	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282		
	LB	5	3	7	6	6	6	2	12/94	Ockert	514	282		
	LC	3	5	4	1	0	0	5	11/17/1970	Strathmann, et al.	210	19		
	LD	5	4	1	1	7	4	5	05/02/1995	Oshlack et al.	424	456		
	LE	5	4	2	6	1	1	2	06/95	Zagon et al.	514	282		
	LF	3	5	4	1	0	0	6	11/17/1970	Bixler, et al.	210	23		
S.T	LG	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
S.T	LH	0	8	8	0	3	5	2	02/03/1998	EP (B1)	A61K	31/485		x
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S.T	LI	Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152.												
	LJ	Hassain et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130.												
	LK	Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) Vol 157, No 2, pp. 420-426.												
	LM	Jones et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37.												
	LN	Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (1992) Vol 260, No. 1, pp. 355-363.												
	LO	King et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exper Res (1997) Vol 21, No 5, pp. 906-909.												
	LP	Kogan et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. In Chem. Path. And Pharm (1977) Vol 18, No. 1, pp 29-34.												
	LQ	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J of Psychiatry (1994) Vol 1, p 151.												
	LR	Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, OO. 73-78.												
S.T	LS	Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No 5, pp. 663-672.												
EXAMINER S.T										DATE CONSIDERED 2/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.			
				FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	MA	5 4 6 0 8 2 6	10/24/1995	Merrill et al.	424	470	
	MB	5 4 7 2 7 1 2	12/05/1995	Oshlack et al.	424	480	
	MC	5 4 7 2 9 4 3	12/95	Crain et al.	514	12	
	MD	5 4 7 8 5 7 7	12/26/1995	Sackler et al.	424	489	
	ME	5 4 8 6 3 6 2	1/96	Kitchell et al.	424	426	
S.T.	MF	5 5 0 0 2 2 7	03/19/1996	Oshlack et al.	424	476	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	MG						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
S.T.	MH	Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pp.810-815					
	MI	Lehman, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) Vol 34, pp. 343-352.					
	MJ	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pp. 1574-1577.					
	MK	Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pp. 157-160.					
	ML	Martin et al. "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim-Forsch./Drug Res. (1999) Vol 49, pp. 599-607.					
	MM	Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. Of Pharm and Exper Thera (1965) Vol 150, No 3. Pp. 437-442.					
	MN	Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pp. 37-46.					
	MO	Mendelson et al., "Buprenorphine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pp. 1095-1101.					
S.T.	MP	Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. Vol 15, No 2., pp 156-166					
EXAMINER			S.T.				
			DATE CONSIDERED 2/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	NA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.		5	5	0	2	0	5	8	3/96	Mayer et al.	514	289		
	NB	5	5	0	8	0	4	2	04/16/1996	Oshlack et al.	424	468		
	NC	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484		
	ND	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		
S.T.	NE	5	5	1	4	6	8	0	5/96	Weber et al.	514	249		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	NF													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	NG	Parwatikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Thera, Vol 14, No. 6, pp 941-948.												
	NH	<del>Parwatikar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354.</del>												
S.T.	NI	Pitts et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271, No 3, pp. 1501-1508.												
S.T.	NJ	Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), Vol 94, pp. 484-490.												
S.T.	NK	Preston et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Exper Thera (1993) Vol 264, No 2 pp. 813-823.												
S.T.	NL	Preston et al., "Effects of Sublingually given naloxone in Opioid -dependant human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pp. 27-34.												
	NM	<del>Bigelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149.</del>												
S.T.	NN	Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts); N-Allylnormorphine During Narcotic Addiction (1953) pp. 8-20.												
EXAMINER  S.T.										DATE CONSIDERED  7/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.									
				FILING DATE: October 27, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T	OA	5	5	3	4	4	9	2	7/96	Aston et al.	514	608	
	OB	5	5	4	9	9	1	2	08/27/1996	Oshlack et al.	424	468	
	OC	5	5	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368	
	OD	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25	
S.T	OE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	OF												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
S.T	OG	Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No 13, pp. 2108-2110.											
	OH	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No 1, pp. 54-58.											
	OI	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213.											
	OJ	Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thera (1995) Vol 33, No 9, 524-529.											
	OK	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258.											
	OL	Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526.											
	OM	Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No 2, pp. 206-217.											
	ON	Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol 28, pp. 49-82.											
S.T	OO	Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arznei-Forsch/Drug Res. (2000) Vol 50, pp. 1015-1022.											
EXAMINER  S.T									DATE CONSIDERED  7/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.									
				FILING DATE: October 27, 2003		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>													
*EXAMINER INITIAL	PA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S.T	PA	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35	
	PB	5	5	8	0	8	7	6	12/96	Crain et al.	514	282	
	PC	5	5	8	5	3	4	8	12/96	Crain et al.	514	12	
	PD	5	5	9	1	4	5	2	01/04/1997	Miller et al.	424	468	
S.T	PE	5	6	0	1	8	4	5	02/11/1997	Buxton et al.	424	495	
<b>FOREIGN PATENT DOCUMENTS</b>													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
													YES NO
	PF												
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
S.T	PG	Benfey, "Function of Myocardial $\alpha$ -Adrenoceptors"; Life Sciences (1982) vol 31, pp. 101-112.											
	PH	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J of Clin Invest. (1988) Vol 82, pp. 1547-1577.											
	PI	Yoburn et al., "Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration"; Brain Research Bulletin (1994), Vol 33, pp. 237-240.											
	PJ	Bunzow et al., "Molecular Cloning and Tissue Distribution of a Putative Member of the Rat Opioid Receptor Gene Family that is not a $\mu$ , $\delta$ , or $\kappa$ opioid receptor type"; FEBS letters (1994) pp. 284-288.											
	PK	Mollereau et al., "ORL 1, a novel member of the opioid receptor family: Cloning, functional expression and localization"; FEBS letters 341 (1994), pp. 33-38.											
	PL	Wang, et al., "cDNA cloning of an orphan opiate receptor gene family member and its splice variant"; FEBS letters 348 (1994) pp. 75-79.											
S.T	PM	Suzuki et al., "Morphine conditioned place preference after chronic treatment with naloxone in the rat"; Research Communications in Substance Abuse (1991) vol 12, No 3, pp. 119-131.											
EXAMINER  S.T								DATE CONSIDERED  7/19/04					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559						
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)						APPLICANT(S): Robert F. KAIKO et al.								
						FILING DATE: October 27, 2003		GROUP: 1615						
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	QA	5	6	1	6	6	0	1	4/97	Khanna et al.	514	399		
	QB	5	6	2	2	7	2	2	04/22/1997	Knott et al.	424	494		
	QC	5	6	2	4	9	3	2	4/97	Qin et al.	514	282		
	QD	5	6	3	3	2	5	9	5/97	Qin et al.	514	282		
S.T.	QE	5	6	3	9	4	7	6	06/17/1997	Oshlack et al.	424	468		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	QF													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S.T.	QG	Press Release "International Patent Application to Be Published on Abuse-Resistant Pain Reliever Being Developed by Perdue Pharma"; August 8, 2001.												
	QH	Paronis et al., "Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats"; J fo Pharm Exper Thera (1991), 259 (2), pp. 582-589.												
	QI	Yoburn et al., "Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Sensitivity"; Pharmacology Bio Beh (1995) Vol 51 No. 2, pp. 535-539.												
	QJ	Crain et al., "Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia"; Brain Research (2001) Vol 888, pp. 75-82.												
	QK	Zhang et al., "Down-Regulation of $\mu$ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy"; Neuroscience (1998) Vol 82., pp. 223-240.												
	QL	Abdulla et al., "Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons"; J of Neuro Sci (1998) Vol 18, pp 9685-9694.												
S.T.	QM	Di Giannuario et al., "Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats"; Neurosci. Lett (1999) Vol 272 pp. 183-186.												
EXAMINER										DATE CONSIDERED				
S.T.										7/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	RA	5	6	5	6	2	9	5	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T	RA	5	6	5	6	2	9	5	08/12/1997	Oshlack et al.	424	468		
	RB	5	6	7	0	1	7	2	09/23/1997	Buxton et al.	424	495		
	RC	5	6	7	2	3	6	0	09/30/1997	Sackler et al.	424	490		
	RD	5	6	8	1	5	8	5	10/28/1997	Oshlack et al.	424	494		
	RE	5	7	6	3	4	5	2	06/09/1998	Miller et al.	514	282		
	RF	5	7	6	7	1	2	5	06/98	Crain et al.	514	282		
	RG	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
	RH	5	7	6	7	1	2	5	06/16/1988	Crain, et al.	514	282		
	RI	6	0	9	6	7	5	6	08/01/2000	Crain, et al.	514	282		
	RJ	6	1	9	4	3	8	2	02/27/01	Crain, et al.	514	2		
	RK	6	3	6	2	1	9	4	03/26/2002	Crain, et al.	514	285		
	RL	6	3	9	5	7	0	5	05/28/2002	Crain, et al.	514	2		
	RM	20	01	00	06	9	6	7	07/05/2001	Crain, et al.	514	253.04		
S.T	RN	20	01	00	18	4	1	3	08/30/2001	Crain, et al.	514	2		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	RO													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
S.T	RP	Ciccocioppo et al., "Effect of Nociceptin/orphanin FQ on the Rewarding Properties of Morphine"; Eur. J Pharmacol (2000) Vol 404, pp. 153-159.												
S.T	RQ	Physician's Desk Reference (2001) see Revia, pp. 1146-1149 and Oxycontin, pp. 2697-2701												
	RR													
	RS													
EXAMINER  S.T										DATE CONSIDERED 7/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Robert F. KAIKO et al.			
						FILING DATE: October 27, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>									
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
S.T	SA	5 8 1 1 2 6	09/22/1998	Krishnamurthy	424	498			
	SB	5 8 3 4 4 7 7	11/10/1998	Mioduszewski	514	282			
	SC	5 8 4 3 4 8 0	12/01/1998	Miller et al.	424	484			
	SD	5 8 4 9 2 4 0	12/15/1998	Miller et al.	264	460			
	SE	5 8 5 8 0 1 7	1/99	Demopulos et al.	604	890.1			
	SF	5 8 6 0 9 5 0	1/99	Demopulos et al.	604	49			
	SG	5 8 6 6 1 6 4	2/99	Kuczynski et al.	424	472			
	SH	5 4 0 9 9 4 4	04/25/1995	Black et al.	514	359			
	SI	5 1 3 0 3 1 1	07/14/1992	Guillaumet et al.	514	234.2			
	SJ	4 4 0 1 6 7 2	08/30/1983	Portoghese	424	260			
	SK	4 4 5 7 9 3 3	07/03/1984	Gordon et al.	424	260			
	SL	5 4 3 6 2 6 5	07/25/1995	Black et al.	514	420			
	SM	5 6 3 9 7 8 0	06/17/1997	Lau et al.	514	419			
	SN	5 6 0 4 2 6 0	02/18/1997	Guay et al.	514	605			
	SO	5 6 0 4 2 5 3	02/18/1997	Lau et al.	514	415			
	SP	5 5 9 3 9 9 4	01/14/1997	Batt et al.	514	252			
	SQ	5 5 3 6 7 5 2	07/16/1996	Ducharme et al.	514	602			
	SR	5 5 5 0 1 4 2	08/27/1996	Ducharme et al.	514	365			
	SS	5 5 2 1 2 1 3	05/28/1996	Prasit et al.	514	443			
	S.T	ST	5 5 1 0 3 6 8	04/23/1996	Lau et al.	514	419		
SU		5 4 7 4 9 9 5	12/12/1995	Ducharme et al.	514	241			
<b>FOREIGN PATENT DOCUMENTS</b>									
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
					YES	NO			
SX									
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
SY									
EXAMINER <div style="text-align: center; font-size: 1.5em;">S.T</div>					DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">2/20/04</div>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Robert F. KAIKO et al.									
						FILING DATE: October 27, 2003		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>															
*EXAMINER INITIAL	TA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
S.T.	TB	5	8	6	9	0	9	7	02/09/1999	Wong et al.	424	473			
	TC	5	8	8	0	1	3	2	3/99	Hill	514	282			
	TD	5	8	9	1	4	7	1	04/06/1999	Miller et al.	424	468			
	TE	5	9	0	8	8	4	8	06/01/1999	Miller et al.	514	282			
	TF	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426			
	TG	5	9	5	8	4	5	2	09/28/1999	Oshlack et al.	424	457			
	TH	3	8	4	5	7	7	0	11/05/1974	Theeuwes et al.	128	260			
	TI	4	0	6	3	0	6	4	12/13/1977	Saunders et al.	219	121			
	TJ	4	0	8	8	8	6	4	05/09/1978	Theeuwes et al.	219	121			
	TK	4	2	9	3	5	3	9	10/06/1981	Ludwig et al.	429	19			
S.T.	TL	4	9	5	7	6	8	1	09/18/1990	Klimesch et al.	264	211.23			
<b>FOREIGN PATENT DOCUMENTS</b>															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
	TM														
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
	TN														
	TO														
	TP														
	TQ														
	TR														
	TS														
EXAMINER <div style="text-align: center; margin-top: 10px;">S.T.</div>										DATE CONSIDERED <div style="text-align: center; margin-top: 10px;">7/20/04</div>					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	UA	5	9	5	8	4	5	9	09/28/1999	Chasin et al.	424	490		
	UB	5	9	6	5	1	6	1	10/12/1999	Oshlack et al.	424	457		
	UC	5	9	6	5	1	6	3	10/12/1999	Miller et al.	424	468		
	UD	5	9	6	8	5	4	7	10/99	Reder et al.	424	449		
	UE	5	9	6	8	5	5	1	10/19/1999	Oshlack et al.	424	456		
	UF	5	9	7	2	9	5	4	10/99	Foss	514	282		
	UG	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16		
S.T.	UH	3	1	7	3	8	7	7	03/16/1965	Jackson et al.	252	138		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO	
	UI													
	UJ													
	UK													
	UL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	UM													
	UN													
	UO													
	UP													
	UQ													
	UR													
	US													
EXAMINER  <div style="text-align: center; font-size: 1.5em;">S.T.</div>										DATE CONSIDERED  <div style="text-align: center; font-size: 1.5em;">7/20/04</div>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	VA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T	VA	6	0	2	4	9	8	2	02/15/2000	Oshlack et al.	424	476		
	VB	6	0	6	8	8	5	5	05/30/2000	Leslie et al.	424	468		
	VC	6	0	7	7	5	3	2	06/20/2000	Malkowska et al.	424	457		
	VD	6	0	7	7	5	3	3	06/20/2000	Oshlack et al.	424	461		
	VE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
	VF	6	1	0	3	2	6	1	08/15/2000	Chasin et al.	424	459		
S.T	VG	6	1	4	3	3	2	2	11/07/2000	Sackler et al	424	459		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	VH													
	VI													
	VJ													
	VK													
	VL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	VM													
	VN													
	VO													
	VP													
	VQ													
	VR													
	VS													
EXAMINER  S.T									DATE CONSIDERED  7/20/04					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.										
				FILING DATE: October 27, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
S.T.	WA	6	1	4	3	3	2	8	11/07/2000	Heafield et al.	424	489		
	WB	6	1	6	2	4	6	7	12/19/2000	Miller et al.	424	468		
	WC	6	2	1	0	7	1	4	04/03/2001	Oshlack et al.	424	476		
	WD	6	2	2	8	8	6	3	05/08/2001	Palermo et al.	514	282		
	WE	6	2	5	4	8	8	7	07/03/2001	Miller et al.	424	468		
	WF	6	2	6	1	5	9	9	07/17/2001	Oshlack et al.	424	457		
S.T.	WG	6	2	7	7	3	8	4	08/21/2001	Kaiko et al.	424	400		
<b>FOREIGN P/TENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	WH													
	WI													
	WJ													
	WK													
	WL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	WM													
	WN													
	WO													
	WP													
	WQ													
	WR													
	WS													
EXAMINER  S.T.										DATE CONSIDERED  7/20/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Robert F. KAIKO et al.									
				FILING DATE: October 27, 2003		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S.T.	XA	6	2	9	4	1	9	5	09/25/2001	Oshlack et al.	424	457	
	XB	6	3	0	6	4	3	8	10/23/2001	Oshlack et al.	424	468	
	XC	6	3	2	6	0	2	7	12/04/2001	Miller et al.	424	468	
	XD	6	3	3	5	0	3	3	01/01/2002	Oshlack et al.	424	457	
	XE	6	3	7	5	9	5	7	04/23/2002	Kaiko et al.	424	400	
	XF	6	3	8	7	4	0	4	05/14/2002	Oshlack et al.	424	480	
	XG	6	3	9	9	0	9	6	06/04/2002	Miller et al.	424	464	
	XH	6	4	7	5	4	9	4	11/05/2002	Kaiko et al.	424	400	
	XI	6	6	2	7	6	3	5	09/30/2003	Palermo, et al.	514	282	
	XJ	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449	
S.T.	XK	6	6	9	6	0	8	8	02/24/2004	Oshlack et al.	424	465	
	XL	6	6	9	6	0	6	6	02/24/2004	Kaiko et al.	424	400	
<b>FOREIGN PATENT DOCUMENTS</b>													
	XM												
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
	XN												
	XO												
	XP												
	XQ												
	XR												
	XS												
	XT												
EXAMINER <div style="text-align: center; margin-top: 10px;">S.T.</div>									DATE CONSIDERED <div style="text-align: center; margin-top: 10px;">2/20/04</div>				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													